ABSTRACT
The structure of histone deacetylase (HDAC) has been characterized with the cloning of HDAC-1 enhancing gene. The histone deacetylase and oncovirus combination approach is based on the fact that the addition of a compound that can reversibly compromise host antiviral genetic programs could enhance oncovirus (OV) growth in tumor cells. In the discovery and development of anticancer therapy, the study of histone deacetylation/acetylation has offered a detailed insight into tumor initiation and progression. The enzymes histone aetyl transferases and HDACs act as both histone substrates and nonhistone proteins. The antitumor toxicity of therapeutic genes can be increased by combining with oncolytic viruses. Some naturally occurring oncolytic viruses such as the vaccinia virus, reovirus, and Newcastle disease virus have been discovered that spare normal tissues and infect only tumor cells. One of the ways is exogenous administration of HDIs as they downregulate antiviral defense in cancer cells and enhance oncolytic efficacy using interferon -sensitive OVs.
